Ashley Gallagher, Editor

Individuals receiving the therapy had an 87% reduction in risk for the composite primary endpoint of virus-related hospitalization or all-cause death by day 28.

The therapeutic is the first biologic launched by LEO Pharma in the United States and is expected to be available in pharmacies by February 2022.

The approval is based on efficacy and safety data from 2 positive phase 3 studies that evaluated a combined study population of 166 individuals, which represented the US population with Cushing syndrome.

Anxiety disorders and depression were cited by more than 80% of oncologists as the types of mental health distress seen most often for patients.

According to a Kaiser Permanente research study, individuals who received COVID-19 vaccination had lower non-COVID-19 death rates than individuals who were unvaccinated.

Investigators found that an additional hour of sleep correlated with a 26% decrease in an infant’s risk of being overweight.

Company is the first to file an ANDA referencing Vasostrict, which had total US sales of $786 million in 2020.

Universal school-based depression screening shows promise addressing mental health conditions in students.

The Board of Trustees of APhA addresses 5 areas in their statement, including importance of wellbeing, root causes of pharmacist burnout, pharmacy benefit manager issues, need for provider status, and some potential solutions.

Abatacept is also approved for adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis, and moderate to severe polyarticular juvenile idiopathic arthritis for children 2 years of age and older.

NRx Pharmaceuticals announces that no new concerns were identified by an independent data safety monitoring board, which recommends continued enrollment.

The findings are consistent with an interim analysis showing that the drug significantly reduced the risk of hospitalization or death for any cause by 89% compared with the placebo.

The data presented shows that at 16 weeks, individuals who added the atopic dermatitis drug to low potency standard-of-care topical corticosteroids experienced 28% achieved clear or almost-clear skin.

Study results show that clonal hematopoiesis of indeterminate potential is associated with a lower likelihood of developing AD.

Results from a study show that elderly individuals who are black or who have an immediate family member with a current or past blood cancer have higher rates of these conditions.

CAR T-cell therapy shows durable long-term survival in patients with refractory LBCL, company’s Kite subsidiary says.

Fast track application is based on positive data in HER2 exon 20 insertion mutations in previously treated patients.

The long-acting antiretroviral therapy is intended to replace antiretroviral regimens for individuals who are virologically suppressed.

Primary and secondary endpoints for which data are available were met in a trial dominated by variants.

FoundationOne CDx is a next-generation sequencing based in vitro diagnostic device for detection, insertion and deletion alterations, and copy number alterations in 324 genes and select gene rearrangements.

The emergency use authorization is based on the agency’s previous analysis of immune response data that supported use of a dose for individuals aged 18 years and older.

Saol Therapeutics also announces the acquisition of 4 plasma-derived hyperimmune products by Kamada, which will be invested to help launch Lyvispah and other pipeline developments.

Results of analysis suggest that pharmacists can play a crucial role in increasing annual vaccinations.

The findings of a study showed that the percentage of “I am satisfied with my job” respondents increased by 28.7% for those in the pilot and decreased by 17.9% for those not in the pilot.

The analysis showed that the synchronization of bilateral anterior temporal and right central EEG signals in β-band tended to decrease for individuals with acute herpes zoster.

Results highlight sustained benefits of avapritinib in patients with advanced systemic mastocytosis.

Families and providers can use a flexible infusion schedule to meet patient needs, Octapharma says.

Certain patients with breast cancer treated with an aromatase inhibitor plus palbociclib (Ibrance) could benefit from an early switch to fulvestrant (Faslodex) plus palbociclib, study finds.

Phase 3 induction study results show that the drug achieved a positive endoscopic response at week 12

Administered 6 months after the 2-dose regimen of BNT162b2, boosting with the Johnson & Johnson vaccine shows a substantial increase in antibody and T-cell responses.